Scantox Group Acquires TwinStrand Biosciences DuplexSeq Nonclinical Genomics Safety Business

Scantox Group Acquires Gentronix Ltd

September 9, 2024

Healthcare Services

Scantox Group, together with its majority owner Impilo, has acquired Gentronix Ltd, a UK-based GLP-compliant genetic toxicology CRO headquartered at Alderley Park. The acquisition expands Scantox's preclinical service platform by adding specialist genetic, skin and ocular toxicology capabilities, bringing the Scantox Group to more than 400 employees across seven European sites.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Quintara Biosciences Acquires Laragen Sanger Sequencing Business from Transnetyx

September 15, 2025

Biotechnology

Quintara Biosciences has completed the acquisition of the Laragen Sanger Sequencing business (formerly operated by Transnetyx), effective September 15, 2025. The purchase preserves local operations and customer service in Los Angeles while expanding Quintara’s California sequencing footprint and capabilities.

ToxStrategies Acquires Clintrex Research Corporation

June 25, 2024

Healthcare Services

ToxStrategies, a Renovus Capital Partners–backed scientific consulting firm based in Katy, Texas, has acquired Clintrex Research Corporation, a Sarasota-based clinical and regulatory development services provider focused on neurodegenerative and CNS therapies. The deal (terms undisclosed) expands ToxStrategies' clinical, regulatory, biostatistics and drug‑development capabilities and is intended to broaden its end‑market reach in the life sciences sector.

Labcorp Acquires Toxikon Corporation

November 18, 2021

Healthcare Services

Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.